Ongoing Research Trials
NAVIGATE ESUS is a descriptor for the world wide clinical trial Multicenter, a randomized,
double-blind, double-dummy, active comparator, event-driven, superiority phase III
study of secondary prevention of stroke and prevention of systemic embolism in patients
with a recent embolic stroke of undetermined source (ESUS). The clinical trial is
actively recruiting patients in TTUHSC El Paso’s Department of Neurology who present
a stroke of undetermined cause.
The study is funded by Bayer Pharmaceuticals and enrollment is open through Sept. 30, 2017.
This pharmaceutical trial was established in response to the clinical need to find
more effective anti-thrombotic medications. Patients enrolled into this study are
randomized into either a blind ASA group or a blind Rivaroxaban group. The purpose
is to develop an oral anticoagulant with a low-risk profile for ESUS patients.
The primary investigator (PI) is Alberto Maud, M.D., and co-investigators include Salvador Cruz-Flores, M.D., Gustavo J. Rodriguez, M.D., and Paisith Piriyawat, M.D.
For more information regarding this clinical trial, please contact Clinical Research Coordinator Israel Alba, M.B.A., at Israel.email@example.com.